Cost-effectiveness of ramipril in cardiovascular risk reduction for patients with diabetes mellitus

被引：0

|

作者：

Ganguly, R

Parasuraman, T

机构：

来源：

DIABETES | 2003年 / 52卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A261 / A262

页数：2

相关论文

共 50 条

[1] Number needed to treat and cost-effectiveness of ramipril in preventing cardiovascular events in patients with diabetes mellitus
Ganguly, R
Parasuraman, T
DIABETES, 2003, 52 : A10 - A11
[2] Cost effectiveness of ramipril treatment for cardiovascular risk reduction
Malik, IS
Bhatia, VK
Kooner, JS
HEART, 2001, 85 (05) : 539 - 543
[3] Cost-effectiveness of ramipril in preventing cardiovascular events in high-risk patients
Ganguly, R
Parasuraman, TV
VALUE IN HEALTH, 2003, 6 (03) : 321 - 322
[4] Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: A Swiss perspective
Sendi, P
Russ, W
Battegay, E
Bucher, H
VALUE IN HEALTH, 2004, 7 (06) : 693 - 693
[5] Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events
Capri, S
Perlini, S
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (06) : 913 - 921
[6] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
Pawlik, D.
Wojcik, R.
Zawodnik, A.
Kaczor, M. P.
VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
[7] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
Gourzoulidis, George
Tzanetakos, Charalampos
Ioannidis, Ioannis
Tsapas, Apostolos
Kourlaba, Georgia
Papageorgiou, Giannis
Maniadakis, Nikos
CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 417 - 426
[8] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
George Gourzoulidis
Charalampos Tzanetakos
Ioannis Ioannidis
Apostolos Tsapas
Georgia Kourlaba
Giannis Papageorgiou
Nikos Maniadakis
Clinical Drug Investigation, 2018, 38 : 417 - 426
[9] COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE
Gourzoulidis, G.
Tzanetakos, C.
Ioannidis, I.
Tsapas, A.
Kourlaba, G.
Papageorgiou, G.
Maniadakis, N.
VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
[10] Ramipril is cost-effective in preventing cardiovascular events in patients with diabetes mellitus
Ganguly, R
Parasuraman, TV
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 525A - 525A

← 1 2 3 4 5 →